Equity Research Database

Institutional Investment Pitches

Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.

Atrium Research's investment thesis on Curaleaf ($CURA.TO) — Q2 2026 | Buyside Digest

$CURA.TONASDAQCuraleaf

NEUTRAL

Atrium Research—CURA.TO

Fund Letter

Q2 2026

Published July 17, 2026

$12.28USD

-10.5% vs last month

$12.96Pitched

-5.2% since pitch

Market Cap$3.4B

P/E (TTM)N/A

52-Wk RangeN/A

Div. YieldN/A

Curaleaf has entered a long-term international bulk flower supply agreement with Cannara Biotech valued at up to $21 million. This partnership not...

— Ben Pirie & Nicholas Cortellucci

BSD Research Exclusive

Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($55/mo) and Pro subscribers.

6,000+ Institutional Pitches

Proprietary AI Analysis

100 Letter Unlocks/Cycle

Already a Research or Pro subscriber? Sign In

◆ Keep Reading

Other investors who've written on Curaleaf

No other institutional pitches found for this ticker yet.